including 4,900 in France.
98% of Servier brand-name medicines
active ingredients are synthesized in France.
100 million patients
treated each day worldwide with Group medicines.
in which the Group’s medicines are distributed
3 major R&D areas
oncology, immune-inflammatory and neurodegenerative diseases, cardiometabolism (life-cycle management).
in clinical development, including 16 new molecular entities (January 2021).
A strong international presence
96% of Group revenue (from brand-name medicines) generated outside France.
16 chemical and pharmaceutical production sites
15 International Centers for Therapeutic Research
and 4 research institutes (2 in France, 1 in Denmark and 1 in Hungary).
€4.7 billion euros in revenue
comprising €3.3 billion for brand-name medicines and €1.4 billion for generic medicines.
23 % of revenue from brand-name medicines invested in R&D
31st largest pharmaceutical Group worldwide
and 2nd largest pharmaceutical Group in France.
A leader position in cardiology in France
5th leading pharmaceutical Group worldwide.
Participation reached 36% of the trade balance surplus in France
in pharmaceuticals and fine chemicals (brand-name medicines), amounting to €1.6 billion.